Home > Research > Scientific Programmes: Clinical Research Programme > H12O-CNIO Haematological Malignacies Clinical Research Unit

Clinical Research Programme

H12O-CNIO Haematological Malignacies Clinical Research Unit

Head of Unit:  Joaquín Martínez
Research highlights

The most relevant achievements of our Group in 2016 were:

  • We reported a phase I clinical trial based on an innovative cell therapy approach using activated and expanded NK cells for Multiple Myeloma (MM). The results of exploring this approach in phase II and III clinical trials are promising.
  • We published the first report of exome sequencing in amyloidosis. We have not found any recurrent mutation.
  • Finally, we redefined the role of stringent complete response by next generation sequencing in Multiple Myeloma.